Amneal Pharmaceuticals reported second quarter 2026 results with net revenue of $796 million, a 10% increase year-over-year. GAAP net income rose 157% to $58 million, or $0.18 diluted EPS, while adjusted EBITDA increased 12% to $206 million and adjusted diluted EPS reached $0.30. The company raised its full-year 2026 guidance for net revenue to $3.10–$3.20 billion and adjusted EBITDA to $750–$780 million. Additionally, Amneal announced a debt repricing of its $2.084 billion Term Loan B in July 2026, reducing the interest spread by 50 basis points to generate approximately $12 million in annual savings. The firm operates as a diversified global biopharmaceutical company specializing in complex generics, specialty medicines, and biosimilars.
